@article {8045,
	title = {Second-line chemotherapy with gemcitabine and carboplatin in paclitaxel-pretreated, platinum-sensitive ovarian cancer patients: A Hellenic Cooperative Oncology Group Study},
	journal = {Gynecologic Oncology},
	volume = {92},
	year = {2004},
	note = {Cited By :30Export Date: 21 February 2017},
	month = {2004},
	pages = {152 - 159},
	abstract = {Objective. Patients with epithelial ovarian cancer (EOC) who relapse more than 6 months following completion of platinum-based primary chemotherapy are considered platinum-sensitive, and can be effectively retreated with cisplatin or carboplatin. The nucleoside analogue gemcitabine has proven activity in both platinum-sensitive and platinum-resistant disease. We conducted a phase II study using the combination of carboplatin and gemcitabine for the treatment of patients with relapsed platinum-sensitive and paclitaxel-pretreated EOC. Methods. Forty-three patients were treated with gemcitabine 1000 mg/m 2, intravenously, over 30 min on days 1 and 8, and carboplatin at AUC 5 on day 1. Courses were administered every 3 weeks on an outpatient basis. Results. Among 37 patients with measurable or evaluable disease, 15 (40.5\%) achieved an objective response including 10 complete and 5 partial responses. The median overall survival was 24.5 months, and the median time to progression for all patients was 9 months. The treatment was well tolerated without toxic deaths; the most common toxicities were Grade 3 or 4 neutropenia, anemia, and thrombocytopenia that occurred in 69\%, 26\%, and 24\% of patients, respectively. Conclusions. The combination of carboplatin and gemcitabine is a well-tolerated outpatient regimen with activity in patients with relapsed platinum-sensitive and paclitaxel-pretreated EOC. However, a randomized prospective study is justified to define whether the addition of gemcitabine to single-agent carboplatin results in improved efficacy in this subset of patients. {\textcopyright} 2003 Elsevier Inc. All rights reserved.},
	keywords = {Carboplatin, Gemcitabine, Platinum-sensitive relapsed ovarian cancer, Second-line chemotherapy},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-0742289996\&doi=10.1016\%2fj.ygyno.2003.09.021\&partnerID=40\&md5=2c0c6b77fd296fff37cdf9160ed85a04},
	author = {Papadimitriou, C.A. and Fountzilas, G. and Aravantinos, G. and Kalofonos, C. and Moulopoulos, L.A. and Briassoulis, E. and Gika, D. and Dimopoulos, M.-A.}
}
